A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Diabetic Macular Edema | Central Retinal Vein Occlusion | Neovascular Age-Related Macular...The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications (Faricimab for neovascular age-related macular degeneration \[nAMD\], diabetic macular edema \[DME\], and retinal vein occlusion; Port Delivery System with Ranibizumab for nAMD) in routine clinical practice. This study will not provide or make recommendations on use of any products including Roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. Participation in this study will not change or influence a patient's standard of care in any way.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 and up
Participation Criteria
Inclusion Criteria:
1. Have provided informed consent, as required per local regulations 2.a) Adult patient, as defined by local regulations and local product label, who is newly initiating treatment (or initiated treatment in the previous visit) with a specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye, according to the investigator's discretion in routine clinical practice; OR 2.b) Adult patient, as defined by local regulations and local product label, who is continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye after initiating that treatment in a Roche interventional trial.
Exclusion Criteria:
1. Concomitant participation of the patient in an investigational ophthalmology clinical trial that includes receipt of any investigational drug or procedure within the last 28 days prior to enrollment (this restriction does not apply to patients who are rolling over from Roche interventional studies and continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study)
Study Location
St. Joseph's Health Care - London
St. Joseph's Health Care - LondonLondon, Ontario
Canada
Contact Study Team
Institut De L'Oeil Des Laurentides
Institut De L'Oeil Des LaurentidesBoisbriand, Quebec
Canada
Contact Study Team
St Joseph's Centre for Mountain Health Services
St Joseph's Centre for Mountain Health ServicesHamilton, Ontario
Canada
Contact Study Team
Clarity eye Institute
Clarity eye InstituteVaughan, Ontario
Canada
Contact Study Team
Retina MD Clinic
Retina MD ClinicSainte-catherine, Quebec
Canada
Contact Study Team
The Retina Centre of Ottawa
The Retina Centre of OttawaOttawa, Ontario
Canada
Contact Study Team
Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR) - Centre Ambulatoire
Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR) - Centre AmbulatoireMontreal, Quebec
Canada
Contact Study Team
Retina Surgical Associates
Retina Surgical AssociatesNew Westminster, British Columbia
Canada
Contact Study Team
Toronto Retina Institute
Toronto Retina InstituteToronto, Ontario
Canada
Contact Study Team
Eye Health MD (Opthalmology)
Eye Health MD (Opthalmology)Montreal, Quebec
Canada
Contact Study Team
- Study Sponsored By
- Hoffmann-La Roche
- Participants Required
- More Information
- Study ID:
NCT05476926